Synergy CHC (SNYR)
NASDAQ:SNYR
Top Page
Synergy CHC
(NASDAQ:SNYR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.60
▼(-63.31% Downside)
Action:ReiteratedDate:04/15/26
The score is held down primarily by weak financial performance (losses, declining revenue, negative equity, and negative cash flows) and bearish technical signals. Mixed but somewhat constructive earnings-call outlook and operational progress are outweighed by financing/covenant pressure and recent negative corporate developments.
Positive Factors
Beverage Early Traction
Q1 2026 beverage sales exceeded all of 2025 and project a multi-million dollar run-rate with established distributor placements and inventory on hand. This demonstrates a scalable product expansion and diversified revenue vector that can sustainably reduce reliance on legacy supplement sales over months to years.
Negative Factors
Negative Equity & High Debt
Persistent negative shareholders' equity combined with substantial outstanding debt meaningfully restricts financial flexibility and increases insolvency risk. Accumulated losses signal structural challenges; durable recovery requires consistent profitable growth or material recapitalization to restore balance sheet health.
Read all positive and negative factors
Positive Factors
Negative Factors
Beverage Early Traction
Q1 2026 beverage sales exceeded all of 2025 and project a multi-million dollar run-rate with established distributor placements and inventory on hand. This demonstrates a scalable product expansion and diversified revenue vector that can sustainably reduce reliance on legacy supplement sales over months to years.
Read all positive factors
Synergy CHC (SNYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.50M
Dividend YieldN/A
Average Volume (3M)136.07K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,303,853
10 Day Avg. Volume89,526
30 Day Avg. Volume136,069
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.78
Price to Sales (P/S)0.60
P/FCF Ratio-7.00
Enterprise Value/Market Cap4.57
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit1.47
Enterprise Value/Ebitda-4.83
Forecast
1Y Price Target
$5.00Price Target Upside206.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Synergy CHC Business Overview & Revenue Model
Company Description
Synergy CHC Corp. provides consumer health care, beauty, and lifestyle products in the United States, Canada, and the United Kingdom. It offers brain health nutritional supplements under the FOCUSfactor brand name; lifestyle products and accessori...
Synergy CHC Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.38M | 34.83M | 42.78M | 38.41M | 40.23M |
| Gross Profit | 20.30M | 23.64M | 32.08M | 12.96M | 25.55M |
| EBITDA | -6.17M | 6.47M | 10.84M | -25.81M | 2.81M |
| Net Income | -12.34M | 2.12M | 6.34M | -32.63M | 1.41M |
Balance Sheet | |||||
| Total Assets | 10.16M | 16.34M | 12.24M | 18.54M | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 2.62M | 687.92K | 632.53K | 1.93M | 1.67M |
| Total Debt | 26.81M | 27.52M | 27.62M | 22.83M | 8.75M |
| Total Liabilities | 33.29M | 32.97M | 39.55M | 52.06M | 16.27M |
| Stockholders Equity | -23.13M | -16.63M | -27.31M | -33.52M | -3.68M |
Cash Flow | |||||
| Free Cash Flow | -2.59M | -4.80M | 421.73K | -8.43M | -1.59M |
| Operating Cash Flow | -2.59M | -4.80M | 421.73K | -8.43M | -1.59M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 4.65M | 4.80M | -2.09M | 8.96M | 1.95M |
Synergy CHC Technical Analysis
Negative
1.63
Price Trends
1.29
Negative
1.60
Negative
2.19
Negative
Market Momentum
-0.21
Positive
21.47
Positive
6.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNYR, the sentiment is Negative. The current price of 1.63 is above the 20-day moving average (MA) of 0.99, above the 50-day MA of 1.29, and below the 200-day MA of 2.19, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 21.47 is Positive, neither overbought nor oversold. The STOCH value of 6.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNYR.
Synergy CHC Peers Comparison
UnderperformOutperform
Sector (51)
SNYR
Synergy CHC
0.62
-1.58
-71.82%
RDGT
Ridgetech
2.32
-147.68
-98.45%
GEG
Great Elm Group
2.00
0.10
5.26%
WGRX
Wellgistics Health Inc
0.14
-3.80
-96.35%
Synergy CHC Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Synergy CHC Amends Term Loan, Issues Contingent Warrant
Negative
Mar 25, 2026
On March 24, 2026, Synergy CHC amended its term loan credit agreement with ACP Agency and lenders, revising the amortization schedule, interest mechanics, pricing, leverage and EBITDA covenants, and rules for using equity issuance proceeds. The co...
Business Operations and StrategyFinancial Disclosures
Synergy CHC Brand License Terminated, Eyes Direct Expansion
Negative
Mar 4, 2026
On February 27, 2026, Synergy CHC Corp. was informed by Gravity Pharma General Trading LLC that Gravity was terminating from inception their Brand License Agreement, originally signed on March 31, 2025 and amended June 30, 2025, which had granted ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.